ATE506948T1 - Verwendung von igf-1-serumspiegel-erhöhenden indolessigsäure-derivaten zur herstellung eines arzneimittels zur behandlung von verschiedenen krankheiten - Google Patents
Verwendung von igf-1-serumspiegel-erhöhenden indolessigsäure-derivaten zur herstellung eines arzneimittels zur behandlung von verschiedenen krankheitenInfo
- Publication number
- ATE506948T1 ATE506948T1 AT03757934T AT03757934T ATE506948T1 AT E506948 T1 ATE506948 T1 AT E506948T1 AT 03757934 T AT03757934 T AT 03757934T AT 03757934 T AT03757934 T AT 03757934T AT E506948 T1 ATE506948 T1 AT E506948T1
- Authority
- AT
- Austria
- Prior art keywords
- igf
- treatment
- serum level
- producing
- increase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/132—Heterocyclic compounds containing only one nitrogen as hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/168—Steroids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/184—Hormones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/60—Feeding-stuffs specially adapted for particular animals for weanlings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Birds (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Insects & Arthropods (AREA)
- Marine Sciences & Fisheries (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2003/011171 WO2005039546A2 (en) | 2003-10-03 | 2003-10-03 | Use of indoleacetic acid derivatives which increase the serum igf-1 level for the preparation of a therapeutical composition for treatment of various diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE506948T1 true ATE506948T1 (de) | 2011-05-15 |
Family
ID=34429223
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03757934T ATE506948T1 (de) | 2003-10-03 | 2003-10-03 | Verwendung von igf-1-serumspiegel-erhöhenden indolessigsäure-derivaten zur herstellung eines arzneimittels zur behandlung von verschiedenen krankheiten |
Country Status (16)
Country | Link |
---|---|
US (2) | US9408405B2 (de) |
EP (1) | EP1670444B1 (de) |
JP (1) | JP4641942B2 (de) |
CN (1) | CN1938018B (de) |
AT (1) | ATE506948T1 (de) |
AU (1) | AU2003273967A1 (de) |
CA (1) | CA2541090C (de) |
CY (1) | CY1116665T1 (de) |
DE (1) | DE60336934D1 (de) |
DK (1) | DK1670444T3 (de) |
ES (2) | ES2365847T3 (de) |
HK (1) | HK1103963A1 (de) |
PT (2) | PT1670444E (de) |
RU (1) | RU2345552C2 (de) |
SI (1) | SI1670444T1 (de) |
WO (1) | WO2005039546A2 (de) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1670444B1 (de) | 2003-10-03 | 2011-04-27 | Veijlen N.V. | Verwendung von igf-1-serumspiegel-erhöhenden indolessigsäure-derivaten zur herstellung eines arzneimittels zur behandlung von verschiedenen krankheiten |
ATE430566T1 (de) | 2003-10-03 | 2009-05-15 | Veijlen N V | Tierfutterzusammensetzung |
WO2005049006A1 (ja) * | 2003-11-21 | 2005-06-02 | Ajinomoto Co., Inc. | 糖尿病治療剤 |
DK2118123T3 (en) | 2007-01-31 | 2016-01-25 | Dana Farber Cancer Inst Inc | Stabilized p53 peptides and uses thereof |
ES2610531T3 (es) | 2007-03-28 | 2017-04-28 | President And Fellows Of Harvard College | Polipéptidos cosidos |
US9063122B2 (en) * | 2008-10-17 | 2015-06-23 | Alfredo Gallegos | Biomodulators for treatment or prevention of disease |
DK2440206T3 (en) * | 2009-06-11 | 2018-11-05 | Dsm Ip Assets Bv | Trigonellin as a muscle stimulant |
US9790186B2 (en) | 2009-07-21 | 2017-10-17 | Trustees Of Dartmouth College | Composition and method for prevention, mitigation or treatment of an enteropathogenic bacterial infection |
ES2711526T3 (es) | 2010-08-13 | 2019-05-06 | Aileron Therapeutics Inc | Macrociclos peptidomiméticos |
RU2639523C2 (ru) | 2011-10-18 | 2017-12-21 | Эйлерон Терапьютикс, Инк. | Пептидомиметические макроциклы и их применение |
JP6450192B2 (ja) | 2012-02-15 | 2019-01-09 | エイルロン セラピューティクス,インコーポレイテッド | トリアゾール架橋した、およびチオエーテル架橋したペプチドミメティック大環状化合物 |
MX362492B (es) | 2012-02-15 | 2019-01-21 | Aileron Therapeutics Inc | Macrociclos peptidomiméticos. |
AU2013337388B2 (en) | 2012-11-01 | 2018-08-02 | Aileron Therapeutics, Inc. | Disubstituted amino acids and methods of preparation and use thereof |
WO2014080640A1 (ja) | 2012-11-26 | 2014-05-30 | 国立大学法人東北大学 | エリスロポエチン発現増強剤 |
RU2524634C1 (ru) * | 2013-06-25 | 2014-07-27 | Государственное научное учреждение Северо-Кавказский зональный научно-исследовательский ветеринарный институт (ГНУ СКЗНИВИ) Российской академии сельскохозяйственных наук | Способ стимуляции роста птицы |
EP3082841B1 (de) * | 2013-12-19 | 2021-03-17 | Puretein Bioscience, LLC | Verfahren zur behandlung eines tieres |
KR102265412B1 (ko) * | 2014-08-13 | 2021-06-14 | 주식회사 엘지생활건강 | 그라민 또는 이의 약학적으로 허용가능한 염을 포함하는 피부 미백, 탄력, 주름개선, 보습 또는 항염증용 화장료 또는 약학 조성물 |
KR20170058424A (ko) | 2014-09-24 | 2017-05-26 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티드모방 거대고리 및 이의 용도 |
CN107106661A (zh) * | 2014-12-16 | 2017-08-29 | 普雷坦生物科技有限责任公司 | 用于增加动物中的血清igf‑1的方法 |
EP3294318A4 (de) | 2015-03-20 | 2019-04-03 | Aileron Therapeutics, Inc. | Peptidomimetische makrozyklen und verwendungen davon |
WO2017035288A1 (en) * | 2015-08-27 | 2017-03-02 | Trustees Of Dartmouth College | Composition and method for prevention, mitigation or treatment of an enteropathogenic bacterial infection |
US20180021326A1 (en) * | 2016-07-23 | 2018-01-25 | Paul Edward Stamets | Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin |
US11701348B1 (en) | 2016-07-23 | 2023-07-18 | Turtle Bear Holdings, Llc | Psilocybin compositions |
US20210069170A1 (en) | 2016-07-23 | 2021-03-11 | Paul Edward Stamets | Tryptamine compositions for enhancing neurite outgrowth |
GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
JP7475702B2 (ja) * | 2018-12-13 | 2024-04-30 | エイム・イムノテック・インコーポレイテッド | 筋痛性脳脊髄炎患者における運動耐容能を改善する方法 |
WO2020212948A1 (en) | 2019-04-17 | 2020-10-22 | Compass Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
CN111407884B (zh) * | 2019-06-24 | 2021-12-07 | 浙江大学 | 促生长激素释放激素激动剂ghrh-a在制备抗衰老药物中的用途 |
JP2022547948A (ja) * | 2019-09-09 | 2022-11-16 | ザ・ユニバーシティ・オブ・シカゴ | 片頭痛の処置のための併用療法 |
WO2021067626A2 (en) | 2019-10-01 | 2021-04-08 | Intima Bioscience, Inc. | Genetic engineering of fungi to modulate tryptamine expression |
EP4061359A4 (de) | 2019-11-19 | 2024-04-17 | Turtle Bear Holdings, LLC | Tryptamin-zusammensetzungen zum erhöhen des neuritenauswuchses |
US20230219889A1 (en) | 2020-05-19 | 2023-07-13 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
WO2022047580A1 (en) * | 2020-09-01 | 2022-03-10 | Magicmed Industries Inc. | Hydroxylated psilocybin derivatives and methods of using |
CN112138028A (zh) * | 2020-10-10 | 2020-12-29 | 南京中医药大学 | 蟾蜍色胺类物质在制备抗抑郁药物中的应用 |
US20230202978A1 (en) | 2022-03-04 | 2023-06-29 | Reset Pharmaceuticals, Inc. | Co-crystal or salt |
CN114870018A (zh) * | 2022-05-12 | 2022-08-09 | 江南大学 | 炎症小体nlrp3抑制剂通过抑制神经系统炎症在制备治疗阿尔茨海默症药物中的应用 |
CN115813918B (zh) * | 2022-09-30 | 2024-04-02 | 中国药科大学 | 吲哚乙酸在制备抑郁症治疗药物中的应用 |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA957281A (en) * | 1970-02-03 | 1974-11-05 | Nathan N. Share | Pharmaceutical compositions containing indole-3-acetic acid derivatives as a skeletal muscle stimulant |
US4025650A (en) | 1975-11-24 | 1977-05-24 | Control Drug, Inc. | Method and composition for preventing nutritional deficiency |
GB1475861A (en) * | 1976-03-19 | 1977-06-10 | Warner Lambert Co | Pharmaceutical composition |
GB1535778A (en) * | 1976-12-06 | 1978-12-13 | Mac Sweeney D | Compounds useful in treatment of unipolar depression |
JPS60199801A (ja) | 1984-03-24 | 1985-10-09 | Masaki Kamata | 動物に対する植物成長ホルモンの投与方法 |
US4687763A (en) * | 1985-02-25 | 1987-08-18 | Massachusetts Institute Of Technology | Composition and method for increasing levels or release of brain serotonin |
US4650789A (en) | 1985-10-15 | 1987-03-17 | Commonwealth Medical Corporation Of America | Method and composition for increasing production of serotonin |
BE1000990A3 (nl) | 1987-10-09 | 1989-05-30 | Picanol Nv | Inrichting voor het op elkaar aansluiten van onderling verplaatsbare elementen, en transportinrichting die eerstgenoemde inrichting toepast. |
GB8727099D0 (en) | 1987-11-19 | 1987-12-23 | Cellena Cell Eng A G | Compositions containing melantonin/homologues |
US4945103A (en) * | 1989-01-17 | 1990-07-31 | Michael Cohen | Method of treating pre-menstrual syndrome |
IT1237472B (it) * | 1989-10-04 | 1993-06-07 | Polifarma Spa | Derivati di acido 3-indolpiruvico, loro procedimento di produzione ed impiego terapeutico. |
US5132113A (en) | 1990-10-26 | 1992-07-21 | Maurizio Luca | Nutritional composition containing essential amino acids |
US5192753A (en) | 1991-04-23 | 1993-03-09 | Mcgeer Patrick L | Anti-rheumatoid arthritic drugs in the treatment of dementia |
ZA928011B (en) * | 1991-10-18 | 1993-06-23 | Alza Corp | Transdermal administration of melatonin. |
GB9214419D0 (en) * | 1992-07-07 | 1992-08-19 | Concannon Peter | Biocidal agents |
JPH0725838A (ja) | 1993-05-13 | 1995-01-27 | Yotsuba Yuka Kk | 疲労の予防または回復のための経口投与剤 |
JP3541969B2 (ja) | 1994-09-29 | 2004-07-14 | 東洋紡績株式会社 | ベットマット |
JP3617102B2 (ja) | 1995-01-27 | 2005-02-02 | 味の素株式会社 | ヒト筋肉疲労の早期回復効果を有するアミノ酸栄養組成物 |
JPH08308580A (ja) * | 1995-05-17 | 1996-11-26 | Takeda Chem Ind Ltd | 組換え型ヒトghrhレセプター蛋白質、その製造法および用途 |
EP0766966A3 (de) * | 1995-09-08 | 2001-02-28 | Eli Lilly And Company | Methode zur Behandlung der Insulinresistenz |
FR2741799B1 (fr) * | 1995-12-04 | 1998-01-02 | Oreal | Utilisation de melatonine dans une composition pour traiter les signes cutanes des etats de fatigue |
EP0873754B1 (de) * | 1996-01-09 | 2003-07-30 | Riken | Aminosäurezusammensetzungen |
FR2746313B1 (fr) * | 1996-03-22 | 1998-04-17 | Adir | Utilisation de la melatonine et des ligands melatoninergiques pour l'obtention de compositions pharmaceutiques destinees a la prevention et au traitement du diabete et des complications diabetiques |
US5958964A (en) * | 1997-02-18 | 1999-09-28 | South Alabama Medical Science Foundation | Use of melatonin to prevent cytotoxic effects of amyloid beta protein |
DE19739763A1 (de) * | 1997-09-10 | 1999-09-23 | Franz Uhl | Vitamin B3/Niacin zur Behandlung von Krankheiten |
US6017946A (en) * | 1997-10-08 | 2000-01-25 | Posner; Robert | Serotonin containing formulation for oral administration and method of use |
WO2000009537A2 (en) | 1998-08-14 | 2000-02-24 | Administrators Of The Tulane Educational Fund | Compounds having growth hormone releasing activity |
EP1109572A4 (de) * | 1998-09-03 | 2004-11-24 | Neuronz Ltd | Neuroprotektion |
IL132366A0 (en) | 1998-10-15 | 2001-03-19 | Cell Pathways Inc | Methods for identifying compounds for inhibition of neoplastic lesions and pharmaceutical compositions containing such compounds |
CN1069050C (zh) * | 1998-12-01 | 2001-08-01 | 周旭生 | 一种治疗糖尿病的中药复方制剂 |
EP1135123B1 (de) | 1998-12-04 | 2004-12-29 | Neurosearch A/S | Verwendung von isatinderivaten als ionenkanalaktivierende mittel |
FR2795323B1 (fr) * | 1999-06-23 | 2001-11-16 | Adir | Utilisation de ligands melatoninergiques pour l'obtention de compositions pharmaceutiques destinees a la prevention ou au traitement des pathologies du systeme gastrointestinal |
CN1088597C (zh) * | 1999-10-26 | 2002-08-07 | 合肥永生制药有限公司 | 尿多酸肽组合物及其用途 |
US20020155163A1 (en) * | 1999-12-27 | 2002-10-24 | Samuel D. Benjamin | Integrated multi-vitamin and mineral combination |
WO2001064205A2 (en) * | 2000-03-02 | 2001-09-07 | The Institutes For Pharmaceutical Discovery, Llc | Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor |
DE10037773C1 (de) * | 2000-08-03 | 2002-08-22 | Hennecke Gmbh | Verfahren und Vorrichtung zum Herstellen von mit Langfasern verstärkten Kunststoff-Formteilen |
DE10109798A1 (de) * | 2001-03-01 | 2002-09-12 | Aventis Pharma Gmbh | Gesundheitsfördernde Zusammensetzung von Verbindungen |
US20030166554A1 (en) * | 2001-01-16 | 2003-09-04 | Genset, S.A. | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists |
JP2002281914A (ja) | 2001-03-27 | 2002-10-02 | Nishi Nippon Green Kk | 魚類、家畜類の栄養活力促進剤の製造方法 |
US20020147155A1 (en) * | 2001-04-06 | 2002-10-10 | Foster Warren G. | Prevention and treatment of endometriosis with aryl hydrocarbon receptor binding ligands |
CN1408397A (zh) * | 2001-09-26 | 2003-04-09 | 北京本元青阳生物科技发展有限公司 | 含褪黑素和益智中药的组合物 |
JP2003137808A (ja) * | 2001-10-26 | 2003-05-14 | Kakunai Juyotai Kenkyusho:Kk | 新規経腸栄養剤の製造法 |
WO2003080068A1 (en) | 2002-03-18 | 2003-10-02 | Pharmacia Corporation | Combination of an aldosterone receptor antagonist and nicotinic acid or a nicotinic acid derivative |
CN1440744A (zh) * | 2003-02-15 | 2003-09-10 | 高景曦 | 纳米包覆退黑激素复合保健品 |
EP1620088A4 (de) | 2003-04-28 | 2007-08-29 | Bayer Pharmaceuticals Corp | Indolessigsäure-derivate und ihre verwendung als pharmazeutische mittel |
ATE430566T1 (de) | 2003-10-03 | 2009-05-15 | Veijlen N V | Tierfutterzusammensetzung |
EP1670444B1 (de) | 2003-10-03 | 2011-04-27 | Veijlen N.V. | Verwendung von igf-1-serumspiegel-erhöhenden indolessigsäure-derivaten zur herstellung eines arzneimittels zur behandlung von verschiedenen krankheiten |
-
2003
- 2003-10-03 EP EP03757934A patent/EP1670444B1/de not_active Expired - Lifetime
- 2003-10-03 US US10/574,467 patent/US9408405B2/en not_active Expired - Fee Related
- 2003-10-03 PT PT03757934T patent/PT1670444E/pt unknown
- 2003-10-03 AU AU2003273967A patent/AU2003273967A1/en not_active Abandoned
- 2003-10-03 SI SI200332019T patent/SI1670444T1/sl unknown
- 2003-10-03 DE DE60336934T patent/DE60336934D1/de not_active Expired - Lifetime
- 2003-10-03 CN CN2003801105778A patent/CN1938018B/zh not_active Expired - Fee Related
- 2003-10-03 WO PCT/EP2003/011171 patent/WO2005039546A2/en active Application Filing
- 2003-10-03 JP JP2005509805A patent/JP4641942B2/ja not_active Expired - Fee Related
- 2003-10-03 AT AT03757934T patent/ATE506948T1/de active
- 2003-10-03 ES ES03757934T patent/ES2365847T3/es not_active Expired - Lifetime
- 2003-10-03 CA CA2541090A patent/CA2541090C/en not_active Expired - Lifetime
- 2003-10-03 DK DK03757934.9T patent/DK1670444T3/da active
-
2004
- 2004-09-28 RU RU2006114743/13A patent/RU2345552C2/ru active
- 2004-09-28 PT PT04765746T patent/PT1667678E/pt unknown
- 2004-09-28 ES ES04765746T patent/ES2326595T3/es not_active Expired - Lifetime
-
2007
- 2007-07-27 HK HK07108228.0A patent/HK1103963A1/xx not_active IP Right Cessation
-
2011
- 2011-07-26 CY CY20111100732T patent/CY1116665T1/el unknown
-
2016
- 2016-07-06 US US15/203,671 patent/US10716778B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1670444B1 (de) | 2011-04-27 |
AU2003273967A1 (en) | 2005-05-11 |
WO2005039546A2 (en) | 2005-05-06 |
CY1116665T1 (el) | 2017-03-15 |
HK1103963A1 (en) | 2008-01-04 |
ES2365847T3 (es) | 2011-10-11 |
CN1938018B (zh) | 2010-09-01 |
JP2007525405A (ja) | 2007-09-06 |
PT1667678E (pt) | 2009-08-05 |
ES2326595T3 (es) | 2009-10-15 |
US10716778B2 (en) | 2020-07-21 |
CA2541090C (en) | 2013-04-16 |
US20080194553A1 (en) | 2008-08-14 |
EP1670444A2 (de) | 2006-06-21 |
DE60336934D1 (de) | 2011-06-09 |
CA2541090A1 (en) | 2005-05-06 |
PT1670444E (pt) | 2011-07-29 |
CN1938018A (zh) | 2007-03-28 |
DK1670444T3 (da) | 2011-08-22 |
RU2345552C2 (ru) | 2009-02-10 |
US20160331725A1 (en) | 2016-11-17 |
SI1670444T1 (sl) | 2011-09-30 |
WO2005039546A3 (en) | 2007-10-04 |
AU2003273967A8 (en) | 2005-05-11 |
JP4641942B2 (ja) | 2011-03-02 |
US9408405B2 (en) | 2016-08-09 |
RU2006114743A (ru) | 2007-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE506948T1 (de) | Verwendung von igf-1-serumspiegel-erhöhenden indolessigsäure-derivaten zur herstellung eines arzneimittels zur behandlung von verschiedenen krankheiten | |
EP1784388B8 (de) | Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen | |
ATE204178T1 (de) | Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin | |
EA200400881A1 (ru) | Азаарилпиперазины | |
JP5271534B2 (ja) | 筋萎縮抑制剤 | |
TW200848064A (en) | Process for producing osteocalcin-containing extract | |
ATE372776T1 (de) | Arzneimittel enthaltend deuterium zur behandlung der zuckerkrankheit | |
ATE535237T1 (de) | Verwendung von fts zur behandlung von malignen erkrankungen | |
ATE540924T1 (de) | Neue kristalline formen von perindopril erbumine | |
US9861664B2 (en) | Traditional chinese medicine complex composite for significantly improving high density lipoprotein concentration in serum and preparation method thereof | |
ATE406904T1 (de) | Eine pharmazeutische kolloidale zusammensetzung enthaltend hyaluronsäure-biopolymere zur behandlung von atemwegserkrankungen | |
JP2005501068A (ja) | 特に眼科分野における適用のための外傷および損傷の治癒および/または修復のための治療に適したアミノ酸組成物 | |
CN1101214C (zh) | 外用消炎止痛药及其生产方法 | |
WO2019098811A2 (ko) | Chp(시클로-히스프로)를 포함하는 골 손실 질환의 예방, 개선 또는 치료용 조성물 | |
JP2007031302A (ja) | アディポネクチン産生促進剤、及び代謝異常症候群予防剤 | |
WO2008009655B1 (de) | Medizinische verwendung von n-phenylpropenoyl-aminosäurederivaten und verwandten verbindungen | |
CN103110609A (zh) | 一种治疗口腔溃疡的涂膜剂及其制备方法 | |
CN107050060A (zh) | 治疗牛皮癣的外用药及药物组合物 | |
JP2003212765A (ja) | 水虫の活動を停止させる溶液 | |
CN101143203A (zh) | 一种具有护肝养胃功能的复方口服液 | |
CN1814282A (zh) | 生物胶原蛋白口服液及其制备方法 | |
CN1239156C (zh) | 一种防止或治疗钙质缺损的口服溶液及其制备方法 | |
CN1201769C (zh) | 治疗糖尿病、肾病的药物 | |
CN1256108C (zh) | 阿胶磷脂组合物及其制备方法 | |
CN105395574A (zh) | 一种药食两用防治心脑血管病复方角鲨烯鱼油软胶囊 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1670444 Country of ref document: EP |